TKIs with vs without upfront SRS for EGFR+ and ALK+ NSCLC and brain metastasis
Biagio Ricciuti shared on X about a recent paper by Luke Pike et al. titled “Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)” published in Journal of Clinical Oncology.
Authors: Luke R.G. Pike, Emily Miao, Lillian Boe, Tejas Patil, Brandon Imber, Nathaniel Myall, Erqi Pollom, Chad Rusthoven et al.
“Next gen TKIs with vs without upfront SRS for patients with EGFR+ and ALK+ NSCLC and brain metastasis.
N=317 – retrospective
- No OS difference
- improved time to CNS PD and local control with TKIs+SRS.”
Source: Biagio Ricciuti/X
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School.
His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.